Because CD146 was expected to be a novel endothelial biomarker that acts as a co-receptor for vascular endothelial growth factor receptor-2 (VEGFR-2) in tumor angiogenesis [25], we chose CD146 as a tumor-targeting molecule for the ultrasound imaging agent. This evidence concerns the gene KDR and neoplasm.